IXICO PLC (IXI)

Industry Biotechnology

This stock can be held in an Investment ISA, SIPP and Investment Account

Sell

8.30p

Buy

9.00p

arrow-up0.00p (+0.00%)

Prices updated at 21 May 2026, 14:58 BST

Prices minimum 15 mins delay

Prices in GBX

IXICO PLC is engaged in providing clinical trial services and technology to evaluate imaging endpoints to pharmaceutical companies.

FTSE All-Share

0.15%

LSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. Mark Robert Warne

CEO

Mr. Bram Goorden

Most recent earnings

30 Sep 2025

Fiscal year end

30 Sep 2025

Employees

79

Head office

15 Long Lane

London

United Kingdom

EC1A 9PN

+44 2037637499

companysecretary@ixico.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. Mark Robert Warne Non-Executive Director, Chairman	-
Dr. Dipti Mahendra Amin Non-Executive Director	-
Ms. Katherine Jane Rogers Non-Executive Director	-
Mr. Grant Robert Nash Executive Director, Chief Financial Officer, Chief Operating Officer and Company Secretary	-
Mr. Bram Goorden Executive Director, Chief Executive Officer	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Unicorn Asset Management Ltd	21,737,555
Unicorn AIM VCT Series 3 ORD	21,737,555
Baronsmead Venture Trust	7,252,830
Octopus Investments Limited	6,586,667
M & G Investment Management	-

Director dealings

Date chevron-l-regular chevron-r-regular	Action
24 Apr 2026	Purchase
24 Apr 2026	Purchase
24 Apr 2026	Purchase
12 Jun 2025	Purchase
12 Jun 2025	Sale

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.